Steroid

Certified Piedmontese Dining for Charity donates $40k to 2,222 Inc.

Retrieved on: 
월요일, 8월 2, 2021
Piedmont, Piedmontese cattle, Piedmontese language

In the Guest Chef Series, Certified Piedmontese invites the nation's foremost chefs to take over Casa Bovina and feature their own tasting menus.

Key Points: 
  • In the Guest Chef Series, Certified Piedmontese invites the nation's foremost chefs to take over Casa Bovina and feature their own tasting menus.
  • Guests can support the cause by making reservations and enjoying an exquisite dining experience executed by a celebrity chef in collaboration with Casa Bovina.
  • "Certified Piedmontese looks to continue expanding this program as an opportunity to raise awareness while sustaining the foundations and nonprofit organizations that provide invaluable support to charitable purposes for the community," said Shane Peed, CEO of Certified Piedmontese.
  • About Certified Piedmontese: Certified Piedmontese is a healthier beef option that doesn't sacrifice flavor or tenderness.

Newly Approved Lupus Drug Based on Discoveries Made in HSS Lab

Retrieved on: 
월요일, 8월 2, 2021
Autoimmune diseases, Medical specialties, Clinical medicine, Medicine, Connective tissue diseases, Hospital for Special Surgery, NewYork–Presbyterian Healthcare System, Lupus, Sjögren syndrome, Immune system

Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.

Key Points: 
  • Much of the groundwork for the development of this drug was done in laboratories at Hospital for Special Surgery (HSS) in the early 2000s.
  • In lupus, however, this receptor is activated even when no infection is present, causing the immune system to instead attack its host.
  • In the lab, Dr. Crow and her team began studying the blood of people with lupus and comparing it to the blood of healthy individuals.
  • In 2003, Dr. Crow and her HSS team were one of three groups to publish research confirming interferon's pivotal role in lupus.

Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

Retrieved on: 
월요일, 8월 2, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Cutaneous lupus erythematosus, Connective tissue diseases, Lupus, William Osler, Autoimmune disease, Sjögren syndrome, Lupus erythematosus

It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.

Key Points: 
  • It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.
  • With the approval of Saphnelo, we now have one more drug that allows us to translate valuable research knowledge into clinical practice with multiple benefits for our patients with lupus."
  • Saphnelo showed benefits on overall lupus disease activity, skin lupus and joints and the ability to taper down steroid doses.
  • The Lupus Foundation of America's research during the 1980s contributed to the development of Saphnelo through its support of research on interferons.

Sparrow Pharmaceuticals Secures $50 Million Series A Financing

Retrieved on: 
화요일, 5월 18, 2021
Pharmaceutical, Health, Clinical trials, Steroid, U.S. Venture Partners, Sparrow Pharmaceuticals, OrbiMed, RiverVest, U.S. Venture Partners, SPARROW PHARMACEUTICALS, ORBIMED, RIVERVEST, U.S. VENTURE PARTNERS

b'Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.

Key Points: 
  • b'Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.
  • OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).
  • This financing will allow the company to accelerate the development of its proprietary oral HSD-1 inhibitor, SPI-62, which targets the source of steroids that cause toxicity in key tissues.
  • To learn more about Sparrow Pharmaceuticals and its pipeline, visit the website at www.SparrowPharma.com .\nSparrow Pharmaceuticals was founded to spare patients the ravages of steroids.

Common Blood Test Identifies Benefits and Risks of Steroid Treatment in COVID-19 Patients

Retrieved on: 
수요일, 7월 22, 2020
Medicine, Clinical medicine, Medical specialties, Blood tests, Immunologic tests, RTT, Biomarkers, C-reactive protein, Dexamethasone, Steroid, Coronavirus disease, RECOVERY Trial

The U.K. RECOVERY trial, a prospective, randomized, open-label study of the steroid dexamethasone versus standard of care, involved more than 6,000 patients with COVID-19.

Key Points: 
  • The U.K. RECOVERY trial, a prospective, randomized, open-label study of the steroid dexamethasone versus standard of care, involved more than 6,000 patients with COVID-19.
  • "We also found that a common blood test may identify the best candidates for steroid treatment."
  • One group of 140 patients was treated with steroids within 48 hours of hospital admission; and a control group of 1,666 similar patients did not receive steroid therapy.
  • Nearly all patients initially had a blood test to measure levels of C-reactive protein (CRP), which the liver produces in response to inflammation.

ZRT Laboratory Launches a New LCMS Saliva Profile to Expand Saliva Test Offerings

Retrieved on: 
금요일, 12월 13, 2019
Medicine, Clinical medicine, Branches of biology, Medical tests, Saliva testing, Bioidentical hormone replacement therapy, Chromatography, Phenols, Steroid, LCMS, Estradiol, Liquid chromatography–mass spectrometry

BEAVERTON, Ore., Dec. 12, 2019 /PRNewswire-PRWeb/ -- ZRT Laboratory is pleased to announce the launch of a new LCMS Saliva Steroid Profile to be added to the existing suite of saliva test offerings.

Key Points: 
  • BEAVERTON, Ore., Dec. 12, 2019 /PRNewswire-PRWeb/ -- ZRT Laboratory is pleased to announce the launch of a new LCMS Saliva Steroid Profile to be added to the existing suite of saliva test offerings.
  • ZRT has therefore developed an assay using liquid chromatography/tandem mass spectrometry (LC-MS/MS, or LCMS).
  • This profile tests a broad range of bioidentical hormones, ethinyl estradiol, and several synthetic hormone synthesis inhibitors, which are all reported together from one convenient saliva sample collection.
  • To learn more about ZRT's new LCMS Saliva Steroid Profile or to order yours today, visit ZRT's saliva page or contact customer service at 866.600.1636 or email [email protected] .

ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

Retrieved on: 
화요일, 11월 26, 2019
Evercore, Steroid, Baudette, Minnesota

BAUDETTE, Minn., Nov. 26, 2019 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston, Massachusetts.Arthur Przybyl, President and CEO, Robert Schrepfer, Senior Vice President Business Development & Specialty Sales, and Mark Ginski, Vice President Cortrophin Product Development, will present at 10:15 AM ET on Tuesday, December 3, 2019.

Key Points: 
  • BAUDETTE, Minn., Nov. 26, 2019 /PRNewswire/ --ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston, Massachusetts.Arthur Przybyl, President and CEO, Robert Schrepfer, Senior Vice President Business Development & Specialty Sales, and Mark Ginski, Vice President Cortrophin Product Development, will present at 10:15 AM ET on Tuesday, December 3, 2019.
  • The presentation will be webcast live at http://wsw.com/webcast/evercore4/anip/ .The live webcast will be archived and available through the prior link for 90 days following the presentation.
  • ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.
  • The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

BurgerFi Earns An "A" From Major Consumer And Environmental Groups For Its Commitment To Antibiotic Free Beef

Retrieved on: 
목요일, 10월 18, 2018
Biology, Cattle, Livestock, Beef, BurgerFi, Endocrinology, Angus cattle, Hormone, Steroid

BurgerFi's mission is to serve the top 1% of best-tasting certified, American Black Angus beef from the finest ranches across the country.

Key Points: 
  • BurgerFi's mission is to serve the top 1% of best-tasting certified, American Black Angus beef from the finest ranches across the country.
  • Known for delivering the all-natural burger experience, BurgerFi has a company-wide commitment to quality food that ensures no steroids, antibiotics, growth hormones, chemicals or additives are ever used.
  • "The results from the fourth annual 2018 Chain Reaction Report came as no surprise to us," said Corey Winograd, BurgerFi CEO.
  • BurgerFi uses only 100% natural Angus beef patties with no steroids, antibiotics, growth hormones, chemicals or additives ever used.

Congenital Adrenal Hyperplasia Epiomic Epidemiology Forecasts 2018-2028

Retrieved on: 
월요일, 9월 17, 2018
Adrenal gland disorders, Medicine, Endocrine system, Endocrinology, Congenital adrenal hyperplasia, Adrenal gland, Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, Mineralocorticoid, Cytochrome P450 reductase, Glucocorticoid, Steroid, Lipoid congenital adrenal hyperplasia

The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids.
  • This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics.
  • CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity.